← Back to searchRecruitingRecruiting
Correction of Psoriatic T Cell Signatures by Deucravacitinib
NCT05858645 · University of California, San Francisco
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
This is a one-arm, open-label study to examine the effect of deucravacitinib on cutaneous and blood immune cells of psoriatic patients. 25 subjects with moderate to severe psoriasis will be enrolled. Biopsy and blood samples will be collected before and during treatment and undergo molecular profiling to assess for deucravacitinib-corrected signatures.
Eligibility criteria
Inclusion Criteria:
1. 18 years of age or older
2. Patients with moderate-severe psoriasis (BSA \>= 10%, PASI \>=12, static Physician's Global Assessment (sPGA) 3 and above)
Exclusion Criteria:
1. taking systemic immunosuppressives in the last 12 weeks
2. pregnancy
3. severe immunodeficiency (either from genetic or infectious causes).
4. tuberculosis or other active serious infection
5. active systemic malignancy.
6. breast-feeding
7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Study design
Enrollment target: 25 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2023-10-01
Estimated completion: 2026-06
Last updated: 2024-06-27
Interventions
Drug: deucravacitinib
Primary outcomes
- • Change in Psoriasis Area and Severity Index (PASI) score (pre-treatment, 4 months)
Sponsor
University of California, San Francisco · other
With: Bristol-Myers Squibb
Contacts & investigators
ContactRaymond Cho, MD, PhD · contact · rashes@ucsf.edu · 415 575 0524
InvestigatorRaymond Cho, MD, PhD · principal_investigator, University of California, San Francisco
All locations (1)
University of California, San FranciscoRecruiting
San Francisco, California, United States